FOX Business’ Lydia Hu reports on the latest news emerging from the pharmaceutical industry as the U.S.â medication shortage reaches a new record.
Roche is the latest company trying to tap into the highly lucrative weight-loss drug market by fast-tracking its own candidates.
The pharmaceutical giant said that its CT-388 drug is now entering the phase two trial and its CT-996 drug will be moving toward phase two trials next year “based on the encouraging data.” Both come in the form of a pill rather than an injection.
“We are fast-tracking the clinical development of our obesity portfolio with the aim to bring these medications to patients faster than anticipated. We will communicate updated timelines when appropriate,” a Roche spokesperson told FOX Business.
PFIZER ADVANCES ONCE-DAILY WEIGHT-LOSS PILL IN ONGOING STUDY
CEO Thomas Schinecker told the Financial Times in an…
